Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma AB has secured a SEK 30 million credit facility from Hunter Capital, which extends its financial runway to mid-2026. This financial move is expected to enhance the company’s stability and strengthen its position for strategic partnerships with major pharmaceutical players, particularly as it continues to develop its Rheumatoid Arthritis program and engage with regulatory bodies like the EMA and FDA.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company that specializes in resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance and overcoming inflammation.
Average Trading Volume: 215,360
Current Market Cap: SEK755.7M
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.